Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GRI

- PMLiVE

Lilly extends range of cut-price insulins in the US

Announces discounts in response to increasing pricing criticism

Sanofi reception

Sanofi narrows focus, shedding diabetes and cardiovascular research

New CEO Paul Hudson reveals strategy update

- PMLiVE

FDA advisors say no to empagliflozin in type 1 diabetes

Approval of Boehringer, Lilly-partnered drug expansion looks unlikely

- PMLiVE

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Hopes new product can offset continuing decline in franchise

- PMLiVE

Novo bolstered by new diabetes, obesity products

Danish drug-maker has now raised its full-year sales forecast

- PMLiVE

Novo Nordisk taps Noom for digital help with its push into obesity

Could help to strengthen Saxenda franchise in treatment of obesity

- PMLiVE

Novo Nordisk gets FDA okay for new diabetes hope

Potential to combat increasing competition and pricing pressures

- PMLiVE

Novo follows Sanofi, Lilly with insulin price cut in US

Price cut will be effective from January 2020

- PMLiVE

AZ claims first-in-class win for Farxiga in heart failure

AZ in pursuit of class leader Jardiance

- PMLiVE

Novo Nordisk shareholder revolt reaches Europe

Accused of lacking transparency over pricing pressures

- PMLiVE

Novo Nordisk boosted by new type 2 diabetes launches

Rapid uptake of newcomer Ozempic aids growth

- PMLiVE

The fight for affordable insulin

Activists are organised, and demanding action on US insulin prices - and pointing the finger at pharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links